▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2599 by analyst upside · 2026-09-28
MMED
MiniMed Group, Inc.
Healthcare · Market Cap $6B · P/E 0x
ANALYST PRICE TARGET
+24.7%
implied upside to consensus target
Current Price $19.98
Consensus Target $24.92
Bull Target $29.0
Bear Target $15.0
Analysts Covering 12
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
9
Hold
1
Sell
1
52-Week Low $10.65
52-Week High $24.43
YTD Return +8.1%
FUNDAMENTALS
Market Cap $6B
P/E Ratio (TTM) N/A
Forward P/E 31.4x
EPS (TTM) $-1.12
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $3.2B
Profit Margin -9.7%
52-WEEK RANGE
52-Week Low $10.65
52-Week High $24.43
Current Price $19.98
Bear Target $15.0
Bull Target $29.0
● Now $19.98 ● Target $24.92
TRADING DATA
Avg Volume 1.7M
YTD Return +8.1%
Analyst Count 12
Consensus Buy
Upside to Target +24.7%
Last Updated 2026-09-28

ANALYST SUMMARY

MiniMed Group, Inc. (MMED) is currently trading at $19.98 with a Wall Street consensus price target of $24.92, implying potential upside of 24.7% over the next 12 months. 12 analysts currently cover MMED, with a consensus rating of Buy - 83% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $29.0, while the most cautious has a target of $15.0.

MMED operates in the Healthcare sector with a market capitalisation of $6B. The stock is up 8.1% year-to-date and is currently trading near the upper end of its 52-week range of $10.65 – $24.43.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for MMED, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Truist Securities ● Initiated
Buy 2026-09-24 Building track record
Morgan Stanley - Reiterated
Overweight → Overweight 2026-09-03 Building track record
Citigroup - Reiterated
Buy → Buy 2026-09-02 Building track record
Evercore ISI Group - Reiterated
Outperform → Outperform 2026-09-02 Building track record
Wells Fargo - Reiterated
Overweight → Overweight 2026-09-02 Building track record
UBS - Reiterated
Buy → Buy 2026-09-02 33% win rate (6 calls)
Mizuho - Reiterated
Outperform → Outperform 2026-09-02 Building track record
B of A Securities - Reiterated
Buy → Buy 2026-09-02 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
58
out of 100
Coverage depth
20/30
Consensus clarity
16/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →